Preclinical Research

 
News Articles for Preclinical Research top ^
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and β-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The positive data, presented during a poster session on January 9 at MYC: From Biology to Therapy, a meeting of the American Association of Cancer Research (AACR) in La Jolla, Calif., provide additional insights into the parameters that impact the delivery and activity of DsiRNA therapeutics utilizing Dicerna’s proprietary EnCore™ lipid nanoparticle (LNP) technology in HCC and CRC tumor models.
Sign-up for Dicerna Pharmaceuticals Presents Positive Preclinical Data on its DsiRNA Therapeutics Targeting MYC and β-Catenin at AACR MYC: From Biology to Therapy Meeting investment picks
VANCOUVER, British Columbia, Oct.
Sign-up for Tekmira Presents Results of Preclinical Studies With Hepatitis B Therapeutic investment picks
- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome - LA JOLLA, Calif.
Sign-up for Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting investment picks
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV - NEW HAVEN, Conn., Oct.
Sign-up for Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting investment picks
MALVERN, Pa., Nov.
Sign-up for TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B investment picks
-Potential Biomarkers of Response to CB-839 Identified in Myeloma Cells -Synergy of CB-839 With Pomalidomide Demonstrated in Multiple Myeloma Models SOUTH SAN FRANCISCO, Calif., Dec.
Sign-up for Calithera Presents Preclinical Study Findings for CB-839 at the 56th American Society of Hematology Annual Meeting investment picks
http://media.marketwire.com/attachments/200906/438805_alios.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1157104&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting investment picks
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation CAMBRIDGE, Mass., Nov.
Sign-up for Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting investment picks
Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J. , Oct.
Sign-up for Celsion Presents Preclinical Data for its TheraSilence™ Platform at the miRNA World Conference Workshop on miRNA Delivery investment picks
LOS ANGELES , Oct.
Sign-up for CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia investment picks
-- Data Published Online in the Journal of the American Society of Nephrology --
Sign-up for Ardelyx's Tenapanor Reduces Phosphorus Absorption and Protects against Vascular Calcification in Preclinical In Vivo Model of Chronic Kidney Disease investment picks
http://media.marketwire.com/attachments/201402/227789_CBLI_logo2012.jpg http://media.marketwire.com/attachments/201411/81742_roswell.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158724&ProfileId=051205&sourceType=1 BUFFALO, NY --
Sign-up for Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer investment picks
Sustained Immune Responses Protecting the Lung and Nose Against RSV Challenge Seen GAITHERSBURG, Md.
Sign-up for Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium investment picks
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the data presentations on Company and partner experimental therapies to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco, CA.
Sign-up for ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition investment picks
Another Active Immunotherapy Product Added to Inovio's Growing Cancer R&D Pipeline PLYMOUTH MEETING, Pa.
Sign-up for Inovio Pharmaceuticals Melanoma DNA Immunotherapy Inhibits Tumor Growth and Increases Survival in Preclinical Study investment picks
SOUTH SAN FRANCISCO, Calif., Nov.
Sign-up for OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Preclinical Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Precision Manufacturing  |  Next: Preference Shares